G-CON at a glance
G-CON Manufacturing designs, builds and installs prefabricated G-CON POD® cleanrooms for pharmaceutical and biotech companies. G-CON’s unique cleanroom solutions provides bioprocessing capacity in a number of dimensions for a variety of uses, from laboratory environments to personalized medicine and production process platforms. G-CON’s POD product is differentiated from other solutions by being a proper “plug-and-play” product with a lower cost of total ownership, faster delivery times, and consistent quality as compared to other solutions. The company is based in Texas, in USA, and today serves customers in North America and Europe.
In 2020 and 2021, G-CON played important role in providing manufacturing capacity for COVID-19 vaccinations when speed of delivery and quality were the most critical requirements. In 2020, the company also launched new standardised POD offering that can be delivered in matter of weeks and the units can be built into a larger facility. The company initiated the expansion of its production facility in Texas to facilitate the growing demand for offsite-built cleanrooms.
In 2021, G-CON started geographic expansion by building up a commercial and engineering team to better cater the Europe market.
The challenges we face
As the biopharma market evolves, emerging modalities, such as cell and gene therapy, manufacturing moving to smaller production batches, and the need to rapidly scale manufacturing, the traditional drug manufacturing process requires rethinking. Conventional cGMP construction projects can be time consuming, disruptive and costly. Global regulatory requirements, design & permitting, contractor and vendor selection, equipment purchase, and validation are just a few elements in a typical project. G-CONs PODs provides advances in all these elements, hence enabling better and more efficient health care which is an integral part of the solution to SDG #3.
What is the outcome?
G-CON contributes to fulfilling pharmaceutical and biopharmaceutical needs while embracing new trends and being a driver for innovation. Being a trustworthy turnkey provider in cleanroom solutions represents a significant development in the bioprocessing space.
Who are the stakeholders?
Key stakeholders range from large pharmaceutical customers to biotech and CDMO companies. Eventually, the ultimate beneficiary of the drug development and manufacturing conducted by these stakeholders are the patients, that get access to better treatment faster.
How big is the effect, and does it last?
The biopharma market has a constant and long term need for PODs to deliver their lifesaving services. PODs are suited to support the rapid production of smaller batch products, notably in cell and gene therapy and in specific segments of monoclonal antibody (mAb) drugs, which are fast-growing segments required in the future.
If G-CON didn’t exist…
Without G-CON’s offsite built, true “plug-and-play” offering, building or expanding bioprocessing capacity would be much slower, more costly and more disruptive, and often with lower quality. This would result in delays in patients getting treatments and introduction of new therapies to the market.
Impact risk: what can go wrong
If G-CON looses its ability for swift delivery and high quality, its customers are likely to turn into other type of cleanroom solutions, which would result in slower manufacturing capacity built-up for critical drugs and vaccines.